Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATG-008 in advanced solid tumors with specific gene alterations
CTR20201615Phase 2Terminated
- Sponsor
- Antengene
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of onatasertib in Nonhematologic neoplasms, hepatocellular carcinoma (HCC), sponsored by Antengene. Started Aug 2020; status: terminated.
02
Drugs
onatasertib
03
Conditions
Nonhematologic neoplasmshepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on CTR20201615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201615.